drugset / Trial / NCT01470677

Tachosil for the Prevention of Symptomatic Lymph Cysts

NCT01470677

Phase 3 Completed 220 enrolled Ruhr University of Bochum
RandomizedParallel-groupTriple-blindPrevention

Summary

This is a randomized trial of 140 women with endometrial or cervical cancer undergoing removal of lymph tissue (lymphadenectomy). The application of 4 tachosil fibrin patches to the pelvic side wall after tissue removal is tested against no such intervention after tissue removal. The primary endpoint is to evaluate the incidence of symptomatic pelvic lymphoceles defined by CTCAE 4.03 grade \>2 within 4 weeks after surgery in women undergoing open or laparoscopic pelvic lymphadenectomy for cervical and endometrial cancer with and without the application of Tachosil® during surgery. The study's hypothesis is that the application of tachosil fibrin patches will significantly reduce the rate of symptomatic lymph cysts.

Timeline

Start
2011-11
Primary completion
2016-01
Completion
2016-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject TachoSil Other / unclassified Other